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1. Introduction 
Edward Meryon, an English doctor, described Duchenne muscular dystrophy (DMD) for the 
first time, but the symptoms and the histology typical of this condition were firstly described 
by Duchenne de Boulogne in 1861. The dystrophin gene (dys) was firstly identified by Kunkel 
and coworkers (Kunkel et al., 1986), while Hoffman and colleagues (Hoffman et al., 1987) 
identified the gene product dystrophin. This protein is lacking in DMD patients’ muscles and, 
due to its essentiality in membrane stability, its absence induces contraction-related membrane 
damage and the activation of the inflammatory cascade, leading to muscle failure, necrosis, 
and fibrosis (Hoffmann and Dressman, 2001; Blake et al., 2002; Palmieri B. and Sblendorio V., 
2006). This condition affects primarily human and animal skeletal and cardiac muscle and it 
is defined as an X-linked recessive disease with the most cases inherited from carrier 
mothers, and about a third of cases occurring as de novo mutations in the infants. DMD is 
present at birth, but clinical symptoms are not evident until 3 to 5 years of age (leg 
weakness, increasing spine kyphosis, and a waddle-like gait) and usually its diagnosis is 
made on the basis of gait spine abnormalities from 4 to 5 years after birth (Dubowitz et al., 
1975; Jennekens et al., 1991). DMD patients display problems in climbing stairs and rising 
up from the floor; they are unable to run, and in a variable way, most of them lose 
ambulation by 7 to 12 years (Iannitti et al., 2010). Moreover, other characteristics of this 
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disease are the progressive loss of respiratory function that can lead to respiratory failure, 
scoliosis, weight loss, cardiomyopathy, and finally death, as a result of respiratory and cardiac 
complications (Iannitti et al., 2010). The continuous muscle wasting, that characterizes this 
pathological condition, puts DMD patients, from 8 to 12 years of age, in wheelchairs with 
scoliosis developing in 90% of boys who use a wheelchair full-time and die in the late teens or 
early twenties due to respiratory/cardiac failure after a worsening of symptoms (Emery, 1993). 
In children with DMD, non-progressive abnormalities of the central nervous system have also 
been observed. In fact, the mean intelligence quotient of these patients is 82 which is 18 points 
under the mean value of the healthy population, while 30% of the patients have a quotient 
under 75 (Bresolin et al., 1994).In particular, verbal intelligence is primarily affected and 80% of 
DMD patients display atypical electroretinography with the most prominent portion of the 
normal electroretinogram, the wave b, that is absent (Billard et al., 1992; Sigesmund et al., 
1994).  
Inflammation, mediated by neutrophils, macrophages and cytokines, also seems to be 
involved in the damage of dystrophic muscles (Whitehead et al., 2006). Gosselin and 
colleagues (Gosselin et al., 2004) described the important role played by inflammation 
showing that a persistent inflammatory response has been observed in dystrophic skeletal 
muscle leading to an alteration in extracellular environment; it includes an increase in 
inflammatory cells, such as macrophages and elevated levels of various inflammatory 
cytokines like tumor necrosis factor alpha (TNF-ǂ) that contributes to muscle degeneration, 
while pro-fibrotic cytokines, such as transforming growth factor beta (TGF-ǃ), can account 
for a progressive fibrosis. Experimental studies, using the DMD mdx mouse model, support 
this fact reporting that the depletion of inflammatory cells, such as neutrophils, cromolyn 
blockade of mast cell degranulation or pharmacological blockade of TNF, reduces necrosis 
of dystrophic myofibers (DeSilva et al., 1987).  
2. Dystrophin 
The human dystrophin gene (13.973 nucleotides), dys, maps at the Xp21.1 locus; it is 
encoded by a 2.25-Mbp gene with 79 exons and 99.4% of its sequence is composed of introns 
(the fully processed transcript is only 14 Kbp) (Kunkel et al., 1986). The DMD gene can 
produce different dystrophin isoforms through alternative promoter usage and splicing of 
pre-mRNA and the predominant isoform is an approximately 427-kDa cytoskeletal protein 
that consists of 3685 amino acids constituting 5% of sarcolemmal protein and 0.002% of total 
striated muscle protein (Hoffman et al., 1987; Koenig et al., 1988).  
Four domains constitute the structure of full length dystrophin, i.e. an N-terminal ‘‘acting 
binding’’ domain, a middle ‘‘rod’’ domain consisting of spectrin-like repeats, a cysteine-rich 
domain encoded by exons 62 to 70 and a C-terminal domain. The last two domains play a key 
role in the assembly of the dystroglycan complex and in the sarcolemmal function (Petrof, 
2002; Palmieri and Sblendorio, 2006). When a mutation and deletion occur in the dystrophin 
gene, as observed in DMD patients, the protein cannot be produced leading to its complete 
absence in muscle fibers. Dystrophin belongs to a group of proteins called dystrophin 
glycoprotein complex (DGC), which also include cytoskeletal actin, the dystroglycan integral 
membrane proteins, the syntrophins, dystrobrevins and ǂ-catulin (Brown et al., 
1997).Dystrophin links the actin intracellular microfilament network to the extracellular matrix 
and its absence changes the level and localization of DGC, making the sarcolemma fragile and 
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muscle fibers prone to degeneration during repeated cycles of muscle contraction and 
relaxation. Actin associates with the N-terminal of dystrophin, in a region displaying two 
calponin homology domains (Corrado et al., 1994; Norwood et al., 2000; Way et al., 1992), 
while the other proteins bind to the C-terminal region of dystrophin. The association of b-
dystroglycan with dystrophin is mediated by a cysteine-rich region of dystrophin that contains 
a protein module with two highly conserved tryptophans (WW domain) and 2 EF-handlike 
motifs (Huang et al., 2000; Jung et al., 1995). Furthermore, b-dystroglycan associates with the 
extracellular protein a-dystroglycan which, in turn, connects to laminin in the extracellular 
matrix (ECM) (Henry et al., 1998; Henry et al., 1999; Hohenester et al., 1999).Dystrophin, 
through its association with actin and dystroglycan, represents a key bridge between the ECM 
and cytoskeleton, playing an important role in the structural integrity of the muscle cell 
membrane. The absence or disruption of dystrophin, observed in DMD, also exerts some 
effects on the central nervous system (CNS) function. In fact the dystrophin role in the 
positioning of receptors and channels is relevant at the synapse level where the neuromuscular 
junction exerts an important role on the synapse structure and function (Hall et al., 1993; Sanes 
et al., 1999). Dystrophin is localized in the deep regions of junctional folds at the post-synaptic 
face (Bewick et al., 1992; Sealock et al., 1991) and, through its association with its complex of 
proteins (Fig. 1), dystrophin plays both structural and signalling roles.  
 
Fig. 1. Complex of proteins associated with dystrophin. 
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Other clinical aspects of the DMD pathophysiology have been reported. These are cognitive 
impairment and lower intelligence quotient (IQ) (average = 85) observed in boys with DMD, 
disordered CNS architecture, abnormalities in dendrites and loss of neurons. Moreover, at 
the biochemical level, the bioenergetics of the CNS is abnormal, and there is an increase in 
the concentration of choline-containing compounds, indicative of CNS pathology.  
Dystrophin expression is regulated by seven independent promoters, three of which 
regulate the expression of full-length isoforms, while four intragenic promoters regulate the 
expression of different short isoforms in various tissues. Two additional isoforms are 
considered to be full-length and are expressed in the brain. The mutation that affects 
dystrophin promoter regions and regulates the expression of brain isoforms, may be the 
cause of neurological symptoms in some patients with DMD. Each of the additional 
transcripts results in the expression of multiple dystrophin proteins (Dp) that are indicated 
according to their molecular weight: Dp427 muscle, Dp427 brain, Dp427 purkinje, Dp260, 
Dp140, Dp116, and Dp71 (Muntoni et al., 2003).These last four variants contain unique first 
exons and lack the actin binding domain, suggesting that they may have functions that are 
different from the ones ascribed to full-length dystrophin. Dp260 in the retina and Dp71 in 
the brain and other tissues restore the integrity of DGC, but only Dp260, the longest of the 
short isoforms, restores some functional integrity in the dystrophic muscle. These findings 
suggest that a better bridge between ECM and actin is more necessary for the improvement 
of dystrophic muscle function than the one provided by the Dp71 variant.  
Alternative splicing of exons 71 to 74 and 78 increases the diversity of transcripts; the first 
splicing regulates interactions with syntrophins. These exons can be spliced singularly or in 
a different combination, generating a series of in-frame spliced variants. 
The elimination of exons 73 and 74 in any of these transcripts generates a functional protein 
that lacks the syntrophin binding sites (Yang et al., 1995; Newey et al., 2000). The splicing of 
exons gives a translational frame shift, producing the substitution of the last 13 amino acids 
of the predominantly hydrophilic C-terminal region with 31 hydrophobic amino acids. This 
process is regulated in a developmental and tissue- specific way (Tennyson et al., 1996). The 
hydrophobic splice variant is abundant in the cerebral cortex and retina and it serves to 
regulate the binding of dystrophin to ǂ-catulin and its associated proteins (Roberts et al., 
1998). 
3. Searching criteria and aim 
We have been searching Pubmed/Medline, using the key words “Duchenne”, “Muscular” 
and “Dystrophy” combined with “Exon”, “Skipping”, “Immunosuppressant”, “Stem”, 
“Cells”, “Myoblast” and “Transplantation”, in order to collect and analyze all the recent 
advances in DMD, focusing on clinical trials performed in humans. This chapter highlights 
the most promising therapeutical approaches to DMD, i.e. exon skipping and myoblast 
transplantation with some details about the immunosuppressive therapy. 
4. Immunosuppressant drugs 
Among the scientific community there is a growing interest in the use of 
immunosuppressant drugs that may potentially give clinical benefits during the DMD 
course. The interest is due to the host transplant, potential immunosuppressant schedule 
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that should be suitable to increase myoblast or mesangioblast graft survival supporting, in 
the meantime, the autologous crippled mass function. Among immunosuppressant drugs, 
corticosteroids slow DMD progression and, in particular, two corticosteroids, i.e. prednisone 
and deflazacort have been extensively used because of their ability to improve skeletal 
muscle function. Research has also focused on the use of suppressing drugs acting against 
TNF level and suppressing calcineurin signals.  
The long-term effects of deflazacort treatment has been investigated according to two 
treatment protocols from Naples (N) and Toronto (T) in boys, aged between 8 and 15 years, 
who were affected by DMD and had 4 or more years of deflazacort treatment (Biggar et al., 
2001).Thirty seven boys were treated with protocol N, using deflazacort at a dose of 0.6 
mg/kg per day for the first 20 days of the month and no deflazacort for the remainder of the 
month.Vitamin D and calcium were administered daily to boys with osteoporosis. 
Deflazacort treatment started between 4 and 8 years of age. Thirty two were treated with 
protocol T, using deflazacort at a dose of 0.9 mg/kg per day, plus vitamin D and calcium 
daily. Treatment started between 6 and 8 years of age. All boys were monitored every 4 to 6 
months and the results were compared with age-matched control subjects in the two groups 
(19 for protocol N and 30 for protocol T). It was observed that: 1) for the boys treated with 
protocol N, 97% were ambulatory at 9 years (control, 22%), 35% at 12 years (control, 0%) and 
25% at 15 years (control, 0%); 2) for the 32 boys treated with protocol T, 100% were 
ambulatory at 9 years (control, 48%), 83% at 12 years (control, 0%) and 77% at 15 years 
(control, 0%); 3) in boys aged 13 and older, scoliosis developed in 30% of boys in protocol N, 
16% in protocol T, and 90% of control subjects. 30% of boys, who were treated according to 
protocol T, had asymptomatic cataracts, but they did not require any treatment. Fractures 
occurred in 19% of boys in protocol N (controls: 16%) and 16% of boys in protocol T 
(controls: 20%). Summarizing, long term deflazacort treatment has beneficial effects on both 
protocols, although protocol T seems to be more effective and it is frequently associated 
with asymptomatic cataracts. 
The same group (Biggar et al., 2006) designed a study involving 54 boys (30 treated with 
deflazacort), aged between 7 and 15 years, affected by DMD, who were reviewed 
retrospectively. The boys, untreated with deflazacort, stopped walking at 9.8 ± 1.8 years, 
while 7 out of 30 treated boys stopped walking at 12.3 ± 2.7 years (P < 0.05). Among the 23 
boys who were still walking, 21 were 10 year older; pulmonary function was significantly 
greater in 15 year old treated boys (88% ± 18%) than in untreated boys (39% ± 20%) 
(P<0.001). Between 9 and 15 years, the treated boys were shorter and, between 9 and 13 
years, the treated boys weighed less. After 13 years, the treated boys maintained their 
weight, whereas the untreated boys lost weight. Asymptomatic cataracts developed in 10 
out of 30 boys who had received deflazacort.  
Another clinical study compared the course of 74 boys, aged from 10 to 18 years, and 
affected by DMD, treated (n = 40) and untreated (n = 34) with deflazacort (Biggar et al., 
2006). The treated boys were able to rise from a supine condition to standing, climb stairs, 
and walk 10 m without aids from 3 to 5 years longer than the untreated boys. After 10 years 
of age, the treated boys had a significantly better pulmonary function than the untreated 
boys and, after 15 years of age, 8 out of 17 untreated boys required nocturnal ventilation 
unlike the 40 treated boys. As for boys older than 15 years of age, 11 out of 17 untreated 
boys required assistance with feeding unlike the treated boys. Towards 18 years, 30 out of 34 
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untreated boys had a spinal curve greater than 20° if compared with 4 out of the 40 treated 
boys. By 18 years of age, 7 out of 34 untreated boys had lost 25% or more of their body 
weight (treated 0 out of 40) and four of those 7 boys required a gastric feeding tube. By 18 
years of age, 20 out of 34 untreated boys had cardiac left ventricular ejection fractions, less 
than 45% if compared with 4 out of the 40 treated boys and 12 out of 34 died in their second 
decade (17.6 ± 1.7 years), primarily of cardiorespiratory complications. Two out of 40 boys, 
treated with deflazacort, died at 13 and 18 years of age from cardiac failure. The treated 
boys were significantly shorter, did not have excessive weight gain, and 22 out of 40 had 
asymptomatic cataracts. Long bone fractures occurred in 25% of boys in both the treated 
and untreated groups. The authors conclude that these long-term observations are the 
most encouraging. The major benefits of daily deflazacort appear to be the prolonged 
ambulation, improvement in cardiac and pulmonary functions, delay in the need for 
spinal instrumentation, and a greater independence for self-feeding. According to the 
described last two studies, deflazacort has a significant impact on health, quality of life, 
and healthcare costs for boys with DMD and their families and it is associated with a few 
side effects.  
Houde and coworkers (Houde et al., 2008) collected data over an 8-year period for 79 
patients with DMD, 37 of whom were treated with deflazacort. Deflazacort (dose of 0.9 
mg/kg adjusted to a maximum of 1 mg/kg according to the side effects) was started when 
the boys showed a functional decline resulting in ambulating difficulties. The mean length 
of treatment was 66 months. 
The treated boys stopped walking at 11.5 ± 1.9 years, whereas the untreated boys stopped 
walking at 9.6 ± 1.4 years. The cardiac function, assessed by echocardiography every 6 to 12 
months, was better preserved as shown by a normal shortening fraction in treated (30.8% ± 
4.5%) versus untreated boys (26.6% ± 5.7%, P < 0.05), a higher ejection fraction (52.9% ± 6.3% 
treated versus 46% ± 10% untreated), and lower frequency of dilated cardiomyopathy (32% 
treated versus 58% untreated). No change was observed in blood pressure, left ventricle 
end-diastolic diameter, or cardiac mass. Scoliosis was much less severe in treated (14° ± 
22.5°) than in untreated boys (46° ± 224°) and no spinal surgery was necessary in treated 
boys. Limb fractures occurred in 24% of treated and in 26% of untreated boys, whereas 
vertebral fractures occurred in the treated group only (7 out of 37 compared with zero in the 
untreated group). In both groups, weight excess was observed at 8 years of age, and its 
frequency tripled between the ages of 8 and12 years. More patients had weight excess in the 
treated group (13 out of 21 [62%]) than in the untreated group (6 out of 11 [55%]), at 12 years 
of age. Cataracts developed in 49% of treated patients and, in almost all of these patients, 
they developed after at least 5 year treatment. This study underlines that deflazacort use in 
DMD prolongs walking for at least 2 years, slows the decline of vital capacity, and 
postpones the need for mechanical ventilation. The quality of life seems to improve in terms 
of prolonged independence in transfers and rolling over in bed, as well as sitting 
comfortably without having to resort to surgery. 
A study determined and compared the long-term effects of prednisone and deflazacort on 
49 boys, aged between 12 and 15 years, with DMD over a 7-year follow up period (Balaban 
et al., 2005). Eighteen boys were treated with prednisone, 12 with deflazacort, and 19 had no 
drug treatment. Analyzing their lower and upper limb motor functions, pulmonary 
function, prevalence of surgery for scoliosis and side effects, they reached these results: the 
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boys in the steroid groups were significantly more functional and performed better on all 
tests than the untreated boys (P < 0.05); there was no significant difference between 
deflazacort- and prednisone-treated groups (P >0.05); the number of boys having scoliosis 
surgery among the treated groups was significantly less than the one of untreated boys 
(P<0.05); the control group’s capacity had decreased and was significantly less than the one 
of both the prednisone and deflazacort treated boys; both deflazacort and prednisone had 
beneficial effects on the pulmonary function and scoliosis; cataracts, hypertension, 
behavioural changes, excessive weight gain, and vertebral fracture were noted as serious 
side effects. The results of this long-term study are very encouraging and both prednisone 
and deflazacort seem to have a significant beneficial effect on slowing the disease progress. 
Their use in DMD may prolong ambulation and upper limb function with similar potency. 
Both steroids are also able to improve pulmonary function, more than delay the need for 
spinal interventions, with similar therapeutic profiles. 
A study was performed in 17 patients affected by DMD, aged between 17 and 22 years, 
treated with deflazacort (0.9 mg/kg/day) and compared with DMD patients who did not 
receive any treatment, in order to evaluate the involvement of cardiac and 
sternocleidomastoid muscles by means of magnetic resonance imaging (MRI) measurement 
of T2 relaxation time and the left ventricular systolic function (Mavrogeni et al., 2009). This 
study showed that DMD patients, treated with deflazacort, present a better cardiac and 
skeletal profile compared to DMD patients without medication (p<0.001).  
Dubowitz and colleagues (Dubowitz et al., 2002) reported a 5-year follow up of two 4-year-
old boys, with classic DMD with an out-of-frame deletion in the Duchenne gene and 
absence of dystrophin in their muscle, who had a quite remarkable response to an 
intermittent, low dosage regime of prednisolone (0.75 mg/kg per day for 10 days each 
month or alternating 10 days on and 10 days off). In the first case, there was a complete 
remission of all clinical signs of dystrophy, sustained, almost fully, up to the present time; in 
the second case, the initial response was almost as marked, sustained for almost 5 years 
before showing a fairly rapid decline over the ensuing year that resulted in loss of 
independent ambulation at the age of 10. Both boys remained around the 50th percentile as 
for height and weight and showed no evidence of demineralization of bone on consecutive 
dual x-ray absorptiometry scanning of the spine nor any signs of chronic prednisolone 
toxicity. Although this study involved a limited number of patients, it showed that there 
might be an optimal window for treatment in the early stages of the disease and further 
larger-scale controlled studies should be targeted more selectively at this stage of the 
disease. This report also showed that a regime of low-dosage, intermittent prednisolone, 
with cycles of 10 day treatment, either per month or alternating with 10 days off treatment, 
is well tolerated in children affected by DMD. 
Markham and colleagues (Markham et al., 2005) studied the effect of steroids in the cardiac 
function of patients with DMD. They evaluated the left ventricular systolic function and 
cardiac geometry of those subjects through a transthoracic echocardiogram; 111 patients, 
aged 21 years or younger, affected by DMD, were selected. They were divided into two 
groups: untreated (never exposed or treated for less than 6 months) and steroid-treated 
(steroids were administered longer than 6 months); the subjects did not differ in age, height, 
weight, body mass index, systolic and diastolic blood pressure, or left ventricular mass. 
Among the treated patients, 29 received prednisone and 19 received deflazacort. This study 
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showed that treatment, either with prednisone or deflazacort, appears to have an impact on 
the decline in cardiac function seen with DMD. The shortening fraction was significantly 
lower in the untreated group than in the steroid-treated one. The authors concluded that 
deflazacort and prednisone were equally effective in preserving the cardiac function. This 
study shows that the progressive decline in cardiac muscle function can be altered by 
steroid treatment. In particular steroid treatment brings a clinical improvement in 
respiratory and cardiac function in DMD patients, during and beyond their treatment 
period. Moreover, it has the potential to prolong their survival. 
A randomized controlled trial of prednisone and azathioprine, involving 99 boys aged 
between 5 and 15 years and affected by DMD, was conducted with the aim to assess the 
longer-term effects of prednisone and to determine whether azathioprine, alone or in 
combination with prednisone, is able to improve strength (Griggs et al., 1993). The patients 
were divided into 3 groups: placebo; 0.3 mg/kg prednisone per day; 0.75 mg/kg prednisone 
per day. After 6 months, 2 to 2.5 mg/kg azathioprine per day was added to the first two 
groups and placebo added to the third group. The study showed that the beneficial effect of 
prednisone (0.75mg/kg per day) is maintained for at least 18 months and it is associated 
with a 36% increase in muscle mass. Weight gain, growth retardation, and other side effects 
were associated with prednisone and azathioprine did not have any beneficial effect. The 
authors conclude that prednisone beneficial effect is not the result of immunosuppression. 
Kirschner et al. (Kirschner et al., 2008) conducted a randomized, multicenter, double-blind 
placebo-controlled trial. One hundred and fifty three patients were randomized to receive 
either placebo or 4 mg/kg ciclosporin A (CsA). After 3 months, both groups received 
additional treatment with intermittent prednisone (0.75 mg/kg, 10 days on/10 days off) for 
12 months more. In each group, 73 patients were available for intention to treat analysis. 
Baseline characteristics were comparable in both groups. There was no significant difference 
between the two groups concerning primary (manual muscle strength according to the 
Medical Research Council) and secondary (myometry, loss of ambulation, side effects) 
outcome measures. Peak CsA values were measured blindly and ranged from 12 to 658 
ng/mL (mean, 210 ng/mL) in the verum group. According to this study CsA does not 
improve muscle strength as a monotherapy and the efficacy of intermittent prednisone in 
DMD. Calcineurin inhibitors induced chronic nephrotoxicity as reported in a previous study 
(Naesens et al., 2009).  
Sharma and coworkers (Sharma et al., 1993) tested CsA in 15 patients affected by DMD and 
observed an increase in the muscular force generation, measuring the titanic force and 
maximum voluntary contraction (MVC) of both anterior tibial muscles. Normally the titanic 
force and MVC declined during 4 months in patients with DMD. During 8 week CsA 
treatment (5 mg/kg per day), the titanic force significantly increased (25.8% 6 6.6%) and 
MVC (13.6% 6 4.0%) occurred in two weeks’ time. The CsA side effects, gastrointestinal and 
flu-like symptoms were transient and self-limiting. Straathof and colleagues (Straathof et al., 
2009) retrospectively analyzed 35 DMD patients’ data, who were treated with 0.75 mg/kg 
prednisone per day intermittently, 10 days on/10 days off. Prednisone was started during 
the ambulant phase at the age 3.5 up to 9.7 years. The median period of treatment was 27 
months. The authors reported the following results: the median age at which ambulation 
was lost was 10.8 years; 9 patients (26%) had excessive weight gain; 8 boys (21%) had a bone 
fracture that happened when four of those 8 children lost the ability to walk. Treatment was 
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stopped in 2 obese patients, 2 hyperactive boys, and 1 patient after a fracture. Based on the 
previously described data, the authors conclude that prednisone, 10 days on/10 days off, 
has relatively few side effects and extends the ambulant phase for 1 year if compared to 
historical controls. 
5. Exon skipping 
DMD is caused by mutations in the dystrophin gene (Aartsma-Rus et al., 2006; Muntoni, 
2003), leading to disruption of the open reading frame (Fig. 2a). Monaco et al. (Monaco et al., 
1988) found that frame shift mutations in the DMD gene will lead to a truncated and non-
functional dystrophin. Patients with such mutations present less severe Becker muscular 
dystrophy. This reading frame rule holds true for ~91% of DMD cases (Aartsma-Rus et al., 
2006) and has inspired the development of the exon skipping strategy which employs 
antisense oligonucleotides (AON). These small synthetic RNA molecules are complimentary 
to exonic or splice site sequences, thereby, upon hybridization, they are able to modulate 
exon inclusion by the splicing machinery (Manzur et al., 2009; Trollet et al., 2009; van 
Ommen et al., 2008). Although the functionality of the resulting protein may vary, this 
treatment could delay or even stop disease progression and improve function in the 
remaining muscle (Melis et al., 1998; Helderman-van den Enden et al., 2010). The antisense 
oligonucleotides are chemically modified to resist nucleases and promote RNA binding and 
are designed to have high sequence specificity. A lot of studies have provided the proof of 
principle of the therapeutic feasibility of the AON to reframe dystrophin transcripts and 
restore dystrophin synthesis, both in vitro (Aartsma-Rus et al., 2002, 2003, 2004) and in vivo 
using the mdx and DMD mice (Mann et al., 2002; Bremmer-Bout et al., 2004; Heemskerk et 
al., 2009). In studies in the mdx mouse model, oligonucleotides with chemical properties, 
similar to the ones of 2’-O-methyl-phosphorothioate (2’OMePS) RNA, were taken up in 
dystrophin-deficient muscle up to 10 times as much as in healthy muscle tissue, most likely 
owing to increased permeability of the muscle myofiber membrane. In addition, 4 to 8 
weeks’ subcutaneous delivery of the oligonucleotides resulted in a steady increase in 
oligonucleotides levels, exon skipping and dystrophin levels (Heemskerk et al., 2010). 
Exon skipping provides a mutation-specific, and so potentially personalized, therapeutic 
approach for patients with DMD (Fig. 2b). Since mutations cluster around exons 45-55 of 
DMD, the skipping of one specific exon may be therapeutic for patients with a variety of 
mutations. The skipping of exon 51 affects the largest subgroup of patients (approximately 
13%), including the ones with deletions of exons 45 to 50, 48 to 50, or 52 (Aartsma-Rus et al., 
2009). Subsequent clinical trials have shown that two different AON chemistries, either 
2’OMePS (van Deutekom et al., 2007) or phosphorodiamidate morpholino oligomer (PMO) 
(Kinali et al., 2009), targeting DMD exon 51, can restore local dystrophin synthesis in DMD 
patients with no or minimum side effects. However, some relevant points of 
pathophysiologic DMD cascade, such as severe muscle wasting, fibrosis and deficient 
muscle regeneration, may reduce the efficacy of the DMD exon skipping therapy. In 
addition, as DMD patients suffer from muscle degeneration from their early life, myoblasts 
undergo extensive division in an attempt to regenerate, eventually leading to exhaustion of 
the muscle regenerative potential (Yoshida et al., 1998; Hawke et al., 2001; Blau et al., 1985). 
To overcome these problems, there have been several additional therapies in which 
myostatin inhibition has received considerable interest (Kemaladewi et al., 2011). 
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Here we report the three clinical trials based on the exon skipping approach which have 
been performed to date and we describe the trials that are still ongoing. A study, consisting 
in the injection of 0.8 mg of PRO051 into the tibialis anterior muscle, was performed by van 
Deutekom and colleagues (van Deutekom et al., 2007). PRO051 is a 2’OMePS antisense 
oligoribonucleotide complementary to a 20-nucleotide sequence within exon 51. Four 
patients with DMD were included in this study and they all had deletions that were 
correctable by exon-51skipping and had no evidence of dystrophin in the previously made 
diagnostic muscle biopsy. For every patient mutational status and positive exon-skipping 
response to PRO051 in vitro were confirmed, and T1-weighted MRI was used to determine 
the condition of the tibialis anterior muscle. The intramuscular injection of PRO051 induced 
exon-51 skipping, corrected the reading frame, and thus introduced dystrophin in the 
muscle in all four patients affected by DMD. PRO051 restored dystrophin to levels between 
3-12% or 17- 35%, basing on quantification relative to total protein or myofiber content. The 
poorest results that were obtained in a patient, who had the most advanced disease, led the 
authors to underline the importance of using patients at a relatively young age, since in 
them relatively little muscle tissue has been replaced by fibrotic and adipose tissue. Among 
the adverse effects, mild local pain at the injection site was reported by a patient. Mild-to-
moderate pain, after the muscle biopsy, was also reported. Blistering under the bandages 
used for wound closure was reported by two patients. In the period of time elapsing 
between injection and biopsy, flu-like symptoms were observed in two patients and a mild 
diarrhea in a patient.  
A dose escalation intramuscular trial was performed in 7 patients (2 patients received 0·09 mg 
and 5 patients received 0·9 mg of AVI-4658) who received injections in one extensor digitorum 
brevis (EDB) muscle, while the contralateral EDB muscle was injected with 900 μL normal 
saline (Kinali et al., 2009). The 7 patients had deletions in the open reading frame of DMD that 
are responsive to exon 51 and were selected on the basis of the preservation of EDB muscle, as 
assessed by MRI, and the response of cultured fibroblasts from a skin biopsy to AVI-4658. 
Muscles were biopsied between 3 and 4 weeks after injection. No adverse events, related to 
AVI-4658, were reported in this study and they showed an increased dystrophin expression in 
all treated EDB muscles. Immunostaining of EDB-treated muscle for dystrophin was 
performed. In the areas of the immunostained sections that were close to the needle track 
through which AVI-4658 was given, 44–79% of myofibres had increased expression of 
dystrophin. In randomly chosen sections of treated EDB muscles, the mean intensity of 
dystrophin staining ranged from 22% to 32% of the mean intensity of dystrophin in healthy 
control muscles (mean 26·4%), and the mean intensity was 17% (range 11–21%) greater than 
the intensity in the contralateral saline-treated muscle. In the dystrophin-positive fibres, the 
intensity of dystrophin staining was up to 42% of that in healthy muscle. Western blot analysis 
detected increased expression of dystrophin in the AVI-4658-treated muscle of all patients who 
received the high dose, and the immunoblot detected expression of dystrophin of the expected 
molecular weight in all patients. This study has led to a dose-ranging systemic study of AVI-
4658 in ambulant patients affected by DMD (ClinicalTrials.gov, number NCT00844597). 
A phase 1-2a study has been conducted to assess the safety, pharmacokinetics and 
molecular and clinical effects of systemically administered PRO051 (Goemans et al., 2011). 
PRO051 was administered subcutaneously for 15 weeks in 12 patients, with each of four 
possible doses (0.5, 2.0, 4.0, and 6.0 mg per kilogram of body weight) given to 3 patients. 
Irritation at the administration site and, during the extension phase, mild and variable 
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proteinuria and increased urinary ǂ(1)-microglobulin levels were reported. The mean 
terminal half-life of PRO051 in the circulation was 29 days. PRO05, at the dose of 2.0 mg per 
kilogram or higher, induced specific exon-51 skipping. In 10 patients new dystrophin 
expression was observed between approximately 60% and 100% of muscle fibers, as 
observed in post-treatment biopsy. New dystrophin expression increased dose-dependently 
up to 15.6% of the expression in healthy muscle. After the 12 week extension phase, a 
modest improvement was observed in the 6 minute walk test (Netherlands National Trial 
Register number, NTR1241). 
 
Fig. 2. a) Duchenne muscular dystrophy is caused by mutations in the dystrophin gene, 
leading to disruption of the open reading frame; b) Exon skipping mechanism in Duchenne 
muscular dystrophy. 
a) 
b) 
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6. Ongoing clinical trials 
Several clinical trials, involving DMD patients, and based on the exon skipping approach 
are ongoing. A phase 1 trial is testing a drug (GSK2402968) that has been designed to skip 
exon 51 of the dystrophin gene, assessing the safety and tolerability of the drug in 
boys/adolescents who are unable to walk. The absorption and processing of the drug in 
their bodies will be also studied. This trial is expected to end in September 2011. A Phase 
1/2 trial is investigating whether the experimental drug PRO044 is safe and effective as a 
therapy for people with DMD with a mutation in a specific region of the dystrophin gene, 
i.e. exon 44. The expecting end date of the trial is December 2011. Another phase 2 trial is 
investigating GSK2402968 (two different doses), a drug that has been designed to skip 
exon 51 of the dystrophin gene. The aim of the study is to determine if an intermittent 
treatment with GSK2402968 will lead to a better long-term safety profile, while 
maintaining its effectiveness. This trial is expected to end in September 2012. A phase 3 
trial is undergoing testing a drug (GSK2402968) that has been designed to skip exon 51 of 
the dystrophin gene. It will assess the effect of GSK2402968 on the muscle function of boys 
with DMD and will monitor the safety of the drug. It is expected to end in December 2012 
(The information contained in this paragraph has been collected from the website 
http://www.musculardystrophy.org/research/clinical_trials/0/duchenne+muscular+dyst
rophy accessed on 18/05/2011). 
7. Cell-based therapy 
The cell-based therapy, or cell transplantation, involves different procedures with injected 
cell pool to correct some functional tissue or organ impairment. Depending on the 
pathology to be treated, the protocol of cell graft is specific. In genetic disorders, cells are 
genetically corrected with ex vivo procedure and grafted. In degenerative disorders, cells 
are amplified and injected. In cancer or infectious pathologies, the cells are selected on the 
base of immunoreacting or immunomodulating properties, amplified and injected in 
patients. The cells can derive from other species (xenotransplantation), other subjects 
(heterologous) or the receiver (autologous). Using cells deriving from other organism, 
xenotransplantation and heterologous transplantation are associated with the 
immunosuppressive therapy which reduces host immune-reaction against graft. It is 
important to decide which cell type to transplant. Based on remaining differentiate ability 
and plasticity, it is possible to choose the stem cell origin (embryonic, foetal or adult), 
progenitor cells or terminally committed cells, and collect them from the tissue of interest. 
Based on remaining differentiated ability and plasticity, it is possible to choose the stem cell 
origin (embryonic, foetal or adult), progenitor cells or terminally committed cells, from a 
selected specific tissue and followed by a process and purification before graft. They are 
frequently amplified and specifically stimulated to increase and improve grafted pool. In 
autologous transplantation treating genetic disorder, the cells are genetically handled to 
revert mutation. Depending on localization of the disorder, the cells are locally or 
systemically injected. The strategies of the cell-based therapy, adopted for DMD, are two: ex 
vivo genetic correction in autologous cells, followed by graft or heterologous injection of 
cells. It allows to evaluate rapidly the improvement or disadvantages of the therapy, 
avoiding severe complications due to impairment in vital muscles. Heterologous 
transplantation allows to inject low-handled healthy cells with the certainty of avoiding dys 
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mutations. Unfortunately, the immunosuppressive therapy is necessary to protect graft from 
host immune system. 
8. Cell types 
In these last few years, stem cells have received a lot of attention for their potential use in 
cell-based therapies for various human diseases including DMD (Lodi et al., 2011; Farini et 
al., 2009). For several years, after they were discovered, the satellite cells were considered as 
the only cells responsible for the growth and maintenance of the skeletal muscle (Le Grand 
and Rudnicki, 2007a; Le Grand and Rudnicki, 2007b). With the improvements of cell-
isolation technology, a number of markers were described to identify a lot of muscular and 
nonmuscular subpopulations able to actively participate in myogenesis. Recent works have 
described the partial identification and characterization of multilineage stem cells derived in 
culture from numerous adult tissues. In the skeletal muscle itself, rather than satellite cells, 
alternative adult multi-lineage progenitor cell populations showed to have a myogenic 
potential: muscle-derived stem cells (MDSCs) (Sarig et al., 2006), muscle side-population 
(mSP) cells (Wognum et al., 2003) and muscle-derived CD133+ progenitors (Peault et al., 
2007). Several works have described how nonmuscular resident stem cells could participate 
in myogenesis: the bone marrow–derived mesenchymal stem cells (BMMSCs) can 
differentiate into mesodermal cells, including myoblasts (Pittenger et al., 1999; Prockop, 
1997) and adult tissue host cells can also contribute to endodermal and ectodermal cell 
lineages (Krause et al., 2001; Mezey et al., 2000). A subpopulation of CD133+ cells that play 
an important role in myogenic development, has been isolated from blood (Torrente et al., 
2004). Furthermore, other stem cells have been identified in the dorsal aorta of avian and 
mammalian species, the so-called mesoangioblasts (Cossu and Bianco, 2003), while the 
pericytes were found in the basement membrane of the vessels (Dellavalle et al., 2007). 
9. Satellite cells 
Satellite cells derive from a progenitor population paired box protein 3 and 7 (Pax3 and 
Pax7, muscle and neural crest development markers) +/+ localized in the central portion of 
the dermomyotome, the dorso-lateral part of the somite. During the fetal development, the 
resident progenitor population generates cells in satellite position around myofibers, which 
are marked by the expression of Pax7, while the limb muscle satellite cells arise from 
hypaxial cells expressing Pax3. (Le Grand and Rudnicki, 2007b). The satellite cells are 
located beneath the basal lamina of mature skeletal muscle fibres, and they are ideally 
positioned to repair degenerating muscle fibres. These quiescent cells are activated to 
proliferate upon muscle injury or when heavily used during activities such as weight lifting 
or running. This proliferation step is necessary to generate sufficient numbers of myoblasts 
for muscle differentiation and myotube formation. In humans, these mononuclear cells are 
most plentiful at birth (estimated at 32% of sublaminar nuclei). Their frequency declines 
postnatally, stabilizing between 1% and 5% of skeletal muscle nuclei in the adult muscle. In 
humans, the proportion of satellite cells in skeletal muscles also decreases with age, and it 
could explain the decreased efficiency of muscle regeneration in older subjects. Satellite cells 
from aged muscle also display reduced proliferative and fusion capacity, as well as a 
tendency to store fat, thus deteriorating their regeneration potential. Satellite cells present an 
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extended proliferative potential and can repopulate extensively the host’s muscle with an 
efficiency unknown in any other experimental situation (Cooper et al., 2006). 
10. Multipotent muscle-derived stem cells 
Recent studies have demonstrated the existence of a population of multipotent muscle-
derived stem cells (MMDSCs), distinct from satellite cells, with high myogenic potential in 
vitro, even after being appropriately stimulated to differentiate into other lineages, such as 
haematopoietic. MMDSCs reside in skeletal muscle sharing the ability to self-renew and 
differentiate into other mesodermal cell types (Farini et al., 2009). MDSCs were isolated on 
the base of their adhesion ability. The cells, obtained by enzymatic digestion of muscle 
tissue, are seeded on a culture dish and, after 1 hour, the medium and non-adherent cells are 
transferred to another dish (preplating). Then, analogous preplates are repeated at 24 hour 
intervals until preplate 6 (pp6) is completed. The cells, which rapidly attach to the surface, 
are mainly fibroblasts (pp1), cells which adhere within 24-48 hours. They are predominantly 
satellite cells (pp2 – pp4) and the population, which settle at the most slowest speed on a 
flask, consists of multipotential stem cells (pp-6). The phenotype of fraction pp6 is described 
as stem cell antigen-1 (sca-1), CD34+ (marker of hematopoietic and satellite cells), CD45-, c-
kit- (markers of hematopoietic cells) with the expression of desmin (marker of myogenic 
cells) on a different level. MDSCs, cultured in vitro, differentiate spontaneously into 
myotubes but, when appropriately stimulated, these cells can also give rise either to 
osteoblasts , chondroblasts , hematopoietic cells or endothelial cells. MDSCs firmly adhere to 
endothelium in mdx muscles microcirculation and then participate in muscle regeneration, 
following an intramuscular injection. Interestingly, they have also been found in muscles, 
after intravenous administration, and their number was higher in muscles, previously 
injured, than in the control ones. The expression of desmin gradually decreases with 
subsequent preplates and in pp6 population only about 10-20% of cells are positive for this 
protein. However, pp6 cells, cultured in standard conditions, spontaneously enter the 
myogenic pathway that is associated with an increased desmin expression. It has also been 
demonstrated that the majority of MDSCs is positive as for desmin. The studies, regarding 
cell viability after transplantation, have shown that more MDSCs survive following 
intramuscular administration, if compared to more differentiated cells (myoblasts). After the 
injection of the same number of either MDSCs or early preplate (EP) cells, the contribution 
to muscle regeneration, 30 and 90 days later, has been even 10 times higher in MDSC group. 
Marked differences have probably been associated with the distinct immunogenicity 
between MDSCs and EP cells. The evaluation of major histocompatibility complex (MHC-1) 
expression in cell membranes of both cell types has revealed that MHC-1 is present in 63% 
of EP cells, whereas only in 0.5% of MDSCs. However, MDSCs are a much less numerous 
cell population if compared to "typical" satellite cells which dominate in EP group. Only one 
clone of MDSCs can be obtained from 105 of cells originally isolated from muscle tissue (Lee-
Pullen and Grounds, 2005). MMDSCs could also be distinguished by flow cytometry. After 
staining with Hoechst 33324, it was possible to characterize a cell population, called skeletal 
muscle side population (SMSP) or simply side population (SP), which is able to extrude dye 
via ATP-binding cassette G2 (ABCG2) multi-drug resistant pump. SP expresses several 
surface markers associated with haematopoietic stem cells (HSCs) including CD45, c-kit, 
Sca-1 and CD34, but no satellite cell markers such as M-cadherin, Pax7 or desmin. SP cells 
can give rise to all hematopoetic lines, both in vitro and in vivo. The question of myogenic 
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potential is more complex. The SP cells, harvested in vitro, do not differentiate 
spontaneously into myocytes. However, cell-mediated inductive interactions trigger 
myogenic potential of SP cells. These cells contain two distinct fractions with myogenic 
potential, such as CD45+ and CD45-, both exhibiting the potential to constitute myogenic 
cells after a co-culture with primary myoblasts. In particular, CD45+ SP are able to integrate 
into regenerating muscle fibres after an intramuscular injection, while the sub-fraction 
CD45- SP has the potential to give rise to adipocytes and osteocyte. Regardless of 
hematopoietic and myogenic potential, SP also displays endothelial trait (CD31+). 
Moreover, it has been shown that SP expresses angiopoietin 2 and the Tie2 receptor, which 
is bound and activated by angiopoietins. It means, that most of the SP cells share partially 
signalling pathways with endothelial/hematopoietic precursor cell populations. SP cells 
demonstrate that lack of Pax7 gene in experimental animals does not influence the number of 
muscle SP cells. Furthermore, Pax7-/- SP cells can differentiate into myotubes when co-
cultured with myoblasts. It indicates that Pax7 gene is not required for myogenic specification 
of SP cells. Finally, forced expression of MyoD induces myogenic differentiation of Pax7-/- SP 
cells, but not pax7-/- myoblasts. All these data suggest that SMSP and satellite cells are distinct 
populations and probably have different origin (Burdzinska et al., 2008). 
11. Blood- and muscle-derived CD133+ progenitors 
CD133+ cells are considered to be haematopoietic and endothelial stem cells of bone 
marrow origin that could give rise to both endothelial cells and myoblasts. Circulating 
human CD133+ cells demonstrate stemness properties and the ability to restore dystrophin 
expression and eventually regenerate the satellite cell pool in dystrophic scid/mdx mouse 
after intra-muscular and intra-arterial delivery. Skeletal muscle CD133+ stem cell have the 
potential to differentiate towards both muscle and endothelium lineages. Dystrophic human 
CD133+ are able to express an exon-skipped version of human dystrophin, after 
transduction with a lentivirus, carrying a construct designed to skip exon 51; therefore their 
ability to participate in muscle regeneration has been examined after transplantation into 
scid/mdx mice. The comparison of two distinct CD133+ cell populations, one from blood 
and one from skeletal muscle, show that the muscle-derived CD133+ stem cells have the 
potential to differentiate towards both muscle and endothelium lineages. Skipped blood and 
muscle-derived Δ49–50 stem cells, fused in vivo with regenerative fibres, express a 
functional human dystrophin and restructure the dystrophin-associated protein complex, as 
shown by plasmalemmal re-expression of a and b-sarcoglycan proteins. Moreover, being 
sometimes located beneath the basal lamina, and distributed along freshly isolated fibres, it 
is interesting to assess whether muscle-derived CD133+ stem cells are able to differentiate 
into satellite cells. Genetically engineered DMD muscle-derived CD133+ cells show a better 
muscle regeneration in terms of spreading and number of positive fibres in comparison with 
the results obtained from blood-derived stem cells. DMD muscle-derived CD133+ cells are 
more efficient than their blood counterpart in the improvement of morphology and 
restoration of the normal skeletal muscle function in dystrophic murine muscles. Human 
CD133+ cells, isolated from muscle or blood, are able to promote muscular- and endothelial- 
differentiation after intra-arterial and intra-muscular delivery. These cells can be injected 
safely in DMD patients, not only without side effects, but also promoting an increase in the 
number of capillaries per muscle fibres. Moreover, DMD CD133+ cells can be genetically 
modified to re-express a functional dystrophy. Unfortunately, several things need to be 
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ameliorated, such as the potential to enhance proliferation of blood-derived CD133+ cells in 
culture and storage for repeated treatments, the relative efficiency of blood-derived cells, 
compared with muscle-derived cells to contribute to muscle nuclei, the strategy to deliver 
myogenic cells chronically to the various sites of sporadic regeneration that occur in 
muscular dystrophies (Farini et al., 2009; Peault et al., 2007). 
12. Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are conventionally defined as adherent, non-hematopoietic 
cells expressing markers such as CD90, CD105, and CD73, and being negative for CD14, 
CD34, and CD45. While originally identified in the bone marrow, MSCs have been extracted 
from numerous tissues including adipose tissue, heart, Wharton’s jelly, dental pulp, 
peripheral blood, cord blood menstrual blood, and, more recently, Fallopian tube. One of 
the major properties of MSCs is the ability to differentiate into various tissues. The 
traditional differentiation properties of MSCs are their ability to become adipocytes, 
chondrocytes, and osteocytes in vitro, after treatment with induction agents. Non-orthodox 
differentiation into other tissues, for example, cells resembling neurons, muscles, hepatocytes 
and pancreatic islets, has also been reported. There is some evidence that MSCs may 
differentiate selectively into tissues that have been injured. The ease of obtaining bone marrow 
sample and myogenic potential of MSCs makes this population an attractive candidate for 
cellular transplantation in cases of diseases associated with muscle dysfunction. However, 
there are still a lot of controversies around the level of myogenic potential of mesenchymal 
cells. Numerous studies were focused on the methodology of induction of MSC differentiation 
into muscle cells. Contrasting results were obtained treating MSCs with DNA 
methyltransferase inhibitor, such as 5-azacitidine, or galectin-1 as the factor initializing 
myogenesis of MSCs (Chan et al., 2006; Liu et al., 2003). Regarding BMMSC myogenic 
potential, interesting results were achieved culturing the cells by a mixture of cytokines and 
growth factors (fibroblast growth factor beta (ǃFGF), forskolin, plateled derived growth 
factor (PDGF), neuregulin and subsequently transfected with gene encoding Notch 1 
intracellular domain (NICD). Following this procedure, cells differentiated into muscle cells 
with the efficacy of 89% (Dezawa et al., 2005). An alternative approach to induce 
myogenesis in MSCs, is the exposure of these cells to myogenic environment. MSCs, co-
cultured with cardiomycytes or satellite cells, differentiated into either cardiac cells or 
myotubes respectively (Fukuhara et al., 2003; Lee et al., 2005). However, the differentiation 
rate in these conditions was highly limited. The fate of MSCs, injected into either skeletal or 
cardiac muscle, was also analyzed (Shi et al., 2004). It has been demonstrated that 
undifferentiated MSCs can undergo myogenesis after an intramuscular administration but, 
similarly to the in vitro studies, the proportion of differentiated cells was barely detectable, 
only 0,44% of transplanted MSCs fused in myotubes. Gene-corrected DMD MSCs restored 
dystrophin expression in co-cultured dystrophic myoblasts through spontaneous cell fusion 
(Goncalves et al., 2006a). Furthermore, a study where dystrophic MSCs transfected by 
recombinant adenovirus, which contains human microdystrophin cDNA, were injected into 
mdx mouse, showed that expression of dystrophin was detected in dystrophic tissue (Xiong 
et al., 2007). A study has also compared MSCs transplantation with and without prior 
differentiation. Cells were injected around the myocardial infarcted area of a rabbit model. 
The improvement in left ventricular function, vascular density and reduction of infarcted 
area did not differ significantly between the two groups. The perspective to transplant 
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undifferentiated mesenchymal stem cells seems to be promising because it does not require 
time-consuming and expensive extracorporeal manipulations in cells (Ichim et al., 2010). 
13. Mesoangioblasts 
Mesoangioblasts are multipotent progenitors of mesodermal tissues, physically associated 
with the embryonic dorsal aorta in avian and mammalian species. Mesoangioblasts are able 
to differentiate into various mesodermal phenotypes. Mesoangioblast-like cells have been 
isolated from vessels of post-natal tissues. Post-natal cells generally express pericytes rather 
than endothelial cell markers, but they are otherwise similar to their embryonic counterparts 
in terms of proliferation and differentiation potency. When wild-type or dystrophic, 
genetically corrected mesoangioblasts are delivered intra-arterially to dystrophic muscle of 
ǂ-sarcoglycan- null mice (a model for limb girdle muscular dystrophy), they induce a 
dramatic functional amelioration of the dystrophic phenotype. This is due to the widespread 
distribution of the donor’s cells through the capillary network and to an intrinsic defect of 
proliferation in the resident satellite cells, a situation that creates a selective advantage for 
the injected donor cells. To proceed with clinical experimentation, it has been considered to 
be crucial that the delivery and muscle homing of mesoangioblasts may be optimized to 
characterize human cells in depth and the protocol needs to be tested in a large animal 
model. Recently, it has been reported that the enhancing delivery of mesoangioblasts leads 
to the complete reconstitution of downstream skeletal muscles in ǂ-sarcoglycan-null 
dystrophic mice. Mesoangioblasts, exposed in vitro to either stromal cell derived factor-1 or 
TNF-ǂ, have showed enhanced transmigration in vitro and migration into dystrophic 
muscle in vivo. Transient expression of ǂ-4 integrins or l-selectin have also produced a 
several-fold increase in migration, both in vitro and in vivo. Mesoangioblasts, transduced 
with a lentiviral vector expressing human microdystrophin and injected scid/mdx mice and 
immunosuppressed dystrophic golden retriever muscular dystrophy (GRMD) dogs, have 
showed a modified mesoangioblasts-induced dystrophin positivity in myofibres. In 
particular, the results of these injections have been promising in the dystrophic dogs with 
improvements in their muscle function and mobility together with an increased dystrophin 
expression. In order to ameliorate the efficiency of the muscle repair by mesoangioblasts, 
cell migration to skeletal muscle has been improved and unspecific trapping in the capillary 
filters of the body, such as liver and lung, has been reduced (Farini et al., 2009). 
14. Bone marrow stem cells 
In the last decade, it has been discovered the contribution of various nonmyogenic cells in 
the regeneration of skeletal muscle, such as bone marrow-derived cells (BMDCs) and the 
circulating haematopoietic cells. With the advent of more sensitive markers, it has been 
demonstrated that BMDCs can enter the sites of muscle regeneration and also contribute to 
the formation of new muscle fibres. Furthermore, similar cells, resident in skeletal muscle, 
appeared to reconstitute the bone marrow and, via this route, enter again and contribute to 
the regeneration of skeletal muscle. In this sense, it has been demonstrated that the 
intravenous injection of either normal HSCs or a novel population of MDSCs into irradiated 
mdx mice resulted in the reconstitution of the haematopoietic compartment of the 
transplanted recipients, the incorporation of donor-derived nuclei into muscle, and the 
partial restoration of dystrophin expression in the affected muscle. Similarly, after the 
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transplantation into immunodeficient mice, BMDCs migrated into areas of induced muscle 
degeneration, underwent myogenic differentiation, and participated in the regeneration of 
the damaged fibres. Following the transplantation in irradiated mice ablated of endogenous 
satellite cells, the transplanted BMDCs were able to occupate the niche of those satellite 
cells. Furthermore, BMDC satellite cells participated in the regeneration of multinucleated 
muscle fibres at high frequency, becoming heritably myogenic. As these results were 
obtained using the whole bone marrow as transplant source, and since it is known to 
contain haematopoietic and non-haematopoietic progenitors, it is possible to speculate that 
the bone marrow could contain such progenitors for muscle and blood. On the other hand, a 
common progenitor with haematopoietic potential could generate myogenic cells due to 
either physiological stimuli and fusion with a myogenic cell (Farini et al., 2009). 
15. Pericytes 
Pericytes wrap around the vascular tube and interdigitate with the endothelial cells in the 
basement membrane of the vessels, playing a fundamental role in the maintenance of 
microcirculation functionality. Pericytes can be mobilized from the adult bone marrow 
under ischemic conditions, and utilized for their contractile capabilities and their multiple 
cytoplasmic processes. It has been demonstrated that pericytes have a high capacity of 
myogenic differentiation because they give rise to a high number of muscular fibres, when 
injected into scid/mdx mice. It has been proposed that the pericyte could be released from 
its position on a vascular tube in the case of a focal injury, functioning as an 
immunomodulatory and trophic mesenchymal stem cell. The activity of the pericyte ensures 
that the field of damage remains limited and that tissue-intrinsic progenitors replace the 
expired cells. As provided by this evidence, these stem cells could represent a good 
candidate for the muscle therapy because they could be isolated from a muscle biopsy and 
therefore easily accessible. They can be cultured in vitro without loss of stem-cell properties 
and are able to regenerate skeletal muscle after muscular and arterial injection. 
Nevertheless, it would be important to determine whether transplanted pericytes can fully 
reconstitute the satellite cell niche as a real functional stem cell. More information are 
needed about the role of pericytes, in both normal and dystrophic skeletal muscle, in order 
to avoid that the injection of these cells into human dystrophic muscle environment could 
elicit pericyte-derived tumours. 
16. Adipocytes 
Adipocytes share the same mesodermal origin with skeletal muscle. An inverse relationship, 
between skeletal muscle mass and adipose tissue mass, is apparent in murine models of 
skeletal muscle dystrophic pathology such as mdx where the relative level of fat tissue, 
within the diseased muscle, has increased. Moreover, in the myostatin-/- mouse, where the 
skeletal muscle mass has hugely increased, the fat tissue mass is reduced substantially. 
Moreover, cell culture studies have demonstrated that myogenic cell lines, when made to 
overexpress adipogenic transcription factors peroxisome proliferator-activated receptor 
gamma (PPARǄ) and CCAAT/enhancer-binding protein alpha (C⁄EBPǂ) lose their 
myogenic marker expression and differentiate into adipocytes, suggesting that the adult 
myoblasts are capable of being reprogrammed to become adipocytes. Furthermore, the 
satellite cell population has been shown to be capable of conversion into the adipocyte 
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lineage, given the correct cues. A more recent work has provided good evidence that the 
adipocyte lineage can also undergo conversion into myoblasts. An adipocyte-specific stem 
cell population that expressed high levels of CD13, CD44, CD73 and CD90 and was negative 
for CD34, CD45, CD56 and CD184, suggesting mesenchymal stem cell-like characteristics, 
was recently isolated and has shown to display myogenic markers and fuse with maturing 
myofibres when co-cultured with myoblast cell lines. Furthermore, it has been 
demonstrated that cells, isolated from the stromal vascular fraction of adipose tissue, which 
have been shown to differentiate in vitro into adipogenic, chondrogenic, osteogenic and 
myogenic cells, can spontaneously form myotubes when cultured under standard 
conditions in vitro. Furthermore, these cells are able to fuse into myotubes following in vitro 
expansion and following injection into ischaemic murine hind limbs. They also form new 
myofibres and are capable of restoring dystrophin expression in mdx mice, thus displaying 
a therapeutic potential. More recently, a more specific CD45- side population of adipocyte 
progenitor cells, purified from the stromal vascular fraction, has been shown to form 
myofibres in vivo. An array analysis of murine brown fat precursor cell populations has 
recently shown that certain myogenic transcription factors, including myogenin, Myf5 and 
MyoD, are expressed at levels comparable with C2C12 cells within these progenitors. These 
data are in keeping with the previous lineage-tracing studies that showed a 
dermomyotomal origin for brown, but not white, fat precursor cells. Moreover, brown fat 
lineage cells also express the known myogenic microRNAs miR-1 miR-133a and miR-206, 
suggesting that brown adipocytes share a common ancestor with myogenic cells. 
Subsequently, it has been demonstrated that the transcription factor PRD1-BF1-RIZ1 
homologous domain containing 16 (PRDM16), is sufficient and necessary to drive the 
conversion of white adipocytes into brown adipocytes, through an up-regulation of 
uncoupling protein and PPARǄ coactivator-1alpha (PGC1-ǂ) expression. It shows to be a 
key regulator in the formation of the brown fat lineage. PRDM16 drives the brown fat 
lineage by forming a transcriptional complex with C-terminal binding protein 1 or 2, 
whereby it acts to repress white fat-specific genes or complexing with PGC1-ǂ, and PPARǄ 
Coactivator 1-beta (PGC1-ǃ) according to which it enhances expression of brown fat genes. 
Recently, it has been elegantly shown that brown fat cells arise from a Myf5+ common 
precursor that was previously only thought to form skeletal muscle cells. Furthermore, 
PRDM16 overexpression causes brown fat cells to undergo a lineage switch, forming 
skeletal myoblasts through the activation of PPAR-Ǆ, whereas PRDM16- ⁄- brown fat has 
elevated myogenic gene transcription and reduced uncoupling ability. Subsequently, it has 
been shown that human skeletal muscle contains a population of brown fat precursor cells 
that up-regulates uncoupling protein 1 following PPAR-Ǆ agonist treatment. Finally, human 
adipose tissue-derived mesenchymal stem cells have been shown to differentiate into 
myofibres spontaneously as well as induce dystrophin expression following co-culture with 
human DMD myoblasts in vitro through a cell fusion. These data show that adipogenic stem 
cells may be used for therapeutic applications (Otto et al., 2009). 
17. Clinical trials 
Myoblast transplantation is a possible treatment for DMD. Promising results in vivo 
nude/mdx mouse transplantation was obtained and in the 90’s a series of clinical trials on 
DMD patients was conducted. Huard et al. (Huard, et al. 1991; Huard, et al. 1992) 
transplanted myoblasts from an immunocompatible donor into the limb muscles of 4 DMD 
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patients in the advanced stages of the disease. A different degree of dystrophin was detected 
by immunostaining in the patients, but this change slowly decayed over time and it was not 
associated to a strength improvement. Although no immunosuppressive treatment was 
used, no patient showed any clinical sign of rejection. The effects of myoblast 
transplantations, without an immunosuppressive treatment on muscle strength and the 
formation of dystrophin-positive fibers, were studied in five young boys with DMD, using a 
triple blind design. No increase in the static contraction was detected. The expression of 
dystrophin in myoblast-injected fibers was generally low and it decreased to control level in 
6 months. These results strongly suggest that myoblast transplantations, as well as gene 
therapy for DMD, cannot be done without immunosuppression (Tremblay et al., 1993). 
Karpati et al. (Karpati et al., 1993) used cyclophosphamide as an immunosuppressive agent 
to improve the myoblast transfer; however, subsequent experiments demonstrated that this 
antitumour drug killed the transplanted myoblasts, as well as any other rapidly 
proliferating cells. Normal dystrophin was detected, by reverse-transcriptase polymerase 
chain reaction, in DMD patients after myoblast transplantation, but it was not associated to 
an increase in the percentage of dystrophin-positive fibers (Gussoni et al., 1992). 
Immunosuppression of DMD boys by cyclosporine, during myoblast transplantation, 
improved force generation, but it was not effective in replacing clinically significant 
amounts of dystrophin in DMD muscle (Miller et al., 1997). Mendell et al. (Mendell et al., 
1995) injected myoblast, once a month for six months, in 12 DMD patients, but this 
treatment failed to improve strength. Law et al. (Law et al., 1992) demonstrated the 
feasibility and safety of myoblast transplantation, but with a poor clinical improvement. At 
the end of the 90’s, a careful overview of the previous initial trials brought several research 
teams to identify three problems responsible for the limited results observed: (1) 3 days after 
the graft, at least 75% of the transplanted myoblasts died (Fan et al., 1996; Guerette et al., 
1997; Huard et al., 1994); (2) myoblasts were not able to migrate more than 200 μm away 
from the intramuscular injection trajectory (Skuk et al., 1999); (3) if immunosuppression was 
not adequate, the myoblasts were rapidly rejected in less than 2 weeks (Guerette et al., 1994) 
or were induced to activate apoptosis, such as cyclophosphamide usage (Hardiman et al., 
1993; Hong et al., 2002). There are now some solutions to overcome these problems. The 
rapid death of a large percentage of myoblasts can be compensated by the transplantation of 
a high number of cells. Indeed the transplantation of 30 million cells per mm3 has given very 
good results in monkeys (Skuk et al., 1999). In monkeys, the low migration distance of 
myoblasts was avoided by a high number of adjacent intramuscular injections, i.e. 100 
injections per cm2 of muscle surface. High density of intramuscular injections of myoblast in 
11 DMD patients were also well tolerated. One patient received a total of 4,000 
intramuscular injections without any complication. No infection or other complication, 
related to the procedure, was registered (Skuk et al., 2007). An interesting improvement in 
myoblast migration injected in muscle was obtained by the modulation of MyoD expression 
(El Fahime et al., 2000; Smythe and Grounds, 2001). Similarly, it has been observed the 
restoration of 26–30% dystrophin expression in muscle fibers in the environment of the 
irradiated muscle, suggesting an improvement in myoblast migration induced by factors 
released with the irradiated muscle (Cousins et al., 2004; Skuk et al., 2006; Skuk et al., 2007; 
Skuk et al., 2004). The immunosuppression problem was tackled introducing new drugs. 
FK506 (Tacrolimus or Prograf®; Astellas Pharma, Deerfield, IL, USA) allowed to obtain very 
good transplantation results, not only in mice, but also in monkeys (Kinoshita et al., 1996; 
Kinoshita et al., 1994). Unfortunately, FK506 may induce adverse effects in patients 
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(nephrotoxicity, diabetes, increased risk of cancer) if used on an ongoing, long-term basis 
(Palmieri et al., 2010). Many therapeutic protocols were developed to induce specific 
immunological tolerance towards the donor’s myoblasts and through the creation of mixed 
chimerism and central tolerance (Camirand et al., 2004; Stephan et al., 2006). Another 
support to immunosuppression therapy was the transplantation of genetically modified 
autologous myoblasts (Floyd et al., 1998; Goncalves et al., 2006b; Quenneville et al., 2007), or 
avoidance of gradual senescence of differentiated cells, autologous pluripotent stem cells (Di 
Rocco et al., 2006). Other researchers refocus their efforts to optimise the therapy searching 
cell populations thought to be more primitive and less immunologic than myoblasts. They 
include MDSCs (Sarig et al., 2006), mSP cells (Wognum et al., 2003) and muscle-derived 
CD133+ progenitors (Farini et al., 2009). In a double-blind phase I clinical trial, Torrente et 
al. (Torrente et al., 2007) transplanted autologous CD133+ cells, extracted from muscle 
biopsies by intramuscular injection, into eight boys with DMD and sampled after 7 months. 
The cells were not genetically corrected, their fate was not monitored, and the boys were not 
immunosuppressed, because the experiment was designed only to test the safety of the 
implanted cells (grown in culture for only 48 hours). No adverse effects were observed. 
Afterwards, thanks to these observations, the cell therapy was combined with a genetic 
approach: ex vivo introduction of corrective genes into dystrophic CD133+ myogenic cells 
and their subsequent autologous transplantation. The use of exon-skipping for the 
expression of human dystrophin, within the DMD CD133+ cells, allows the use of the 
patient’s own stem cells, thus minimizing the risk of immunological graft rejection (Riviere 
et al., 2006). The exon-skipping therapeutic approach is applicable to gene defects up to 70% 
of DMD patients, and avoids the problems associated with the delivery of the prohibitively 
large full length dystrophin gene or a (less functional) truncated mini-gene. Blood- and 
muscle-derived DMD CD133+ cells were isolated and characterized for their ability to express 
an exon-skipped version of human dystrophin, after infection with a lentivirus carrying a 
construct designed to skip exon 5 (Denti et al., 2006; Goyenvalle et al., 2004). The skipped 
blood and muscle-derived Δ49–50 stem cells were able to fuse in vivo with regenerative fibres 
and expressed, not only a functional human dystrophin, but also the dystrophin-associated 
proteins a and b-sarcoglycans. However, intramuscular transplantations lead only to local 
and focused regeneration, whereas DMD pathology affects the whole body musculature and 
its effective treatment requires some methods to distribute the injected cells to the dispersed 
sites. In future clinical trials, we speculate that these stem cells, purified from DMD patients, 
could be ex vivo engineered and reinjected in the initial donor intra-arterially. The intra-
arterial injections of the patients’own infected stem cells allow the distribution of the cells to 
the whole body musculature so that it could be possible to take care of severely affected 
patients that have a reduced body mass. One of the most important problem to solve, for a 
future clinical application, is the amelioration in safety procedures of the gene 
modifications. Ichim et al. (Ichim et al., 2010) reported the case study of a 22 year-old male 
diagnosed with DMD, treated with a combination of endometrial regenerative cells (ERC) 
and CD34+ umbilical cord blood. Three months later, the patient received another course of 
therapy including placental matrix derived mesenchymal stem cells. The improvement in 
muscular strength, clinical respiratory function and general level of activity are maintained 
to date. No adverse events have been associated with the stem cell infusion. The innovation 
introduced by this trial was the usage of “adjuvant” cellular population which provides a 
more suitable environment for muscle regeneration. The local intramuscular MSCs are able 
to add chemotactic/ trophic support for the intravenously administered CD34. It has been 
www.intechopen.com
 
Muscular Dystrophy 
 
370 
reported that mesoangioblasts, which reside within the CD34 population, as well as cord 
blood CD34 cells, have had positive activity on DMD in animal models, although they 
appear to be short-lived (Jazedje et al., 2009; Nunes et al., 2007; Otto et al., 2009). 
Mesoangioblasts have been the main contributors to de novo myogenesis and were 
selectively attracted into the dystrophic tissue. It is known that CD34 cells express very late 
antigen-4 (VLA-4), which is the ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1), 
whose expression is elevated in dystrophic muscles (Gavina et al., 2006). Furthermore, CD34 
chemokines such as Macrophage inflammatory protein-1 alpha (MIP-1ǂ) and Regulated 
upon activation normal T-cell expressed and secreted (RANTES) expression have been 
found in dystrophic muscle (Demoule et al., 2005). 
18. Conclusions 
According to this review, the attempts to treat DMD with different genetic and cellular 
approaches open new perspectives in the muscular function restoration, although it is very 
difficult to predict, at the moment, what strategy would be more successful. From a lifelong 
perspective, it is reasonable to conceive an integrated schedule of treatment protocols, 
subdivided by decades of age.On this basis, cell transplantation is supposed to be the final 
answer to replace the irreversibly impaired muscle mass with healthy myocytes. It is 
therefore important to choose the best age for the transplant and the best timing schedule is 
probably before the crash of the muscular framework that will be replaced with fibrous and 
adipose tissue. Alternatively , in the very early period of life, when the disease is not 
phenotipically expressed yet, and it is just a genetic biochemical trait, the timing could be 
perfect for either exon skipping or cell transplant approaches that could be more easily 
integrated in the muscular structure. Furthermore, in the homologous cell transplantation, a 
longstanding immunosuppressive phase, which is strongly adversed by the ethical 
committees, is at the moment mandatory in order to achieve an adequate survival of 
nonidentical transplanted cells. These cells should be reasonably replaced with a series of 
transplant sessions in the follow up, as long as their vital cycle will decline to apoptosis. 
Probably, in the next future,even histocompatible cadaver sources might be helpful in the 
long run.  
As to the cell administration route, the transplant procedure, addressed by Cossu and 
coworkers (Sampaolesi et al., 2003; Díaz-Manera et al., 2010), through intra-arterial regional 
perfusion, has to be validated and compared with the more cumbersome repeated 
intramuscular injections for which automatically injecting devices, a proper anesthesia and, 
probably, laparoscopic-thoracoscopic schedule will be required, especially for the deep 
muscles, like diaphragm and heart. In the procedure described by Cossu (Sampaolesi et al., 
2006), according to the results obtained in dog models of DMD, the mesangioblasts can 
easily trespass the endothelial barrier and reach the muscular areas to be restored by new 
healthy myocytes. On the other hand, in the direct intramuscular injections, the operator 
chooses the topography of injections, and, on the basis of mathematical and geometrical 
models, and with the hopeful aid of robotization, a systematic and well arranged 
replacement of several millions of myocytes can be achieved, during each session, on a very 
accurately, individually tailored protocol. The exon-skipping approach is very appealing 
due to the progress observed in the clinical trials, but it is very hard to conceive that this 
genetic correction of the dystrophin gene will be enough effective to support the muscular 
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strength in the developing child, guaranteeing long lasting surrogate effect if introduced in a 
lifelong administration schedule. In this scenario, the oral route is certainly preferred to the 
subcutaneous one, and toxicological studies in mice let us suppose that the compounds are 
safe, but clinical trials in humans require further commitments, especially regarding the 
clinical monitoring of the follow up to determine possible side effects.  
In conclusion, we think that, at the moment, due to brand new strong technological 
weapons, we could achieve a normal life span and quality of life for DMD kids and their 
families. At the same time, we need the collaboration of the centers working on DMD to 
design new clinical trials in order to reach the best effective therapeutic protocol as soon as 
possible. In the “Global Village”, based on the World Wide Web, it is possible to plan panels 
of evidence-based medicine clinical studies by a single international World Wide Web based 
committee, eventually organized by the World Health Organization. This committee will be 
a powerful instrument to meet the urgent demand of the generation of kids with DMD who 
claim to achieve the goal of a fully autonomous life. 
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22. Abbreviations 
2’OMePS: 2’-O-methyl-phosphorothioate  
ABCG2: ATP Binding Cassette G2 
AON: Antisense Oligonucleotide 
BMDC: Bone Marrow Derived Cell 
BMMSC: Bone Marrow Mesenchymal Stem Cell 
ǃFGF: Fibroblast Growth Factor beta 
C⁄EBPǂ: CCAAT/Enhancer Binding Protein alpha 
CNS: Central Nervous System 
CsA: Ciclosporin A 
DGC: Dystrophin Glycoprotein Complex 
DMD: Duchenne Muscular Dystrophy 
Dp: Dystrophin proteins 
Dys: Dystrophin 
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ECM: Extracellular matrix 
EDB: Extensor Digitorum Brevis 
EP: Early Preplate 
ERC: Endometrial Regenerative Cell 
GRMD: Golden Retriever Muscular Dystrophy 
HSC: Haematopoietic Stem Cell 
IQ: Intelligence Quotient 
MDSC: Muscle Derived Stem Cell 
MHC: Major Histocompatibility Complex 
MIP-1ǂ: Macrophage Inflammatory Protein-1 alpha 
MMDSC: Multipotent Muscle Derived Stem Cell 
MRI: Magnetic Resonance Imaging 
MSC: Mesenchymal Stem Cell 
mSP: muscle Side Population 
MVC: Maximum Voluntary Contraction 
N: Naples 
NICD: Notch1 Intracellular Domain 
NTR: Netherlands National Trial Register 
PDGF: Plateled Derived Growth Factor 
PGC1-ǂ: PPARǄ Coactivator 1-alpha 
PGC1-ǃ: PPARǄ Coactivator 1-beta 
PMO: Phosphorodiamidate Morpholino Oligomer 
PPARǄ: Peroxisome Proliferator Activated Receptor gamma 
pp6: preplate 6  
RANTES: Regulated upon Activation, Normal T-cell Expressed and Secreted 
SMSP: skeletal muscle side population 
SP: Side Population 
T: Toronto 
TGF-ǃ: Transforming Growth Factor beta 
TNF-ǂ: Tumor Necrosis Factor-alpha 
VCAM-1: Vascular Cell Adhesion Molecule 1 
VLA-4: Very Late Antigen-4 
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